News
-
Men underestimate skin cancer threat
Thursday | Jun 7 2018ONLY about a third of Aussie men (32%) consider themselves at high risk of skin cancer, despite 82% reporting at least one known risk factor, such as fair hair, skin that burns easily, or spending time outdoors, according to a survey conducted by the Australasian College of Dermatologists.
-
Police seek S8 info
Thursday | Jun 7 2018FEDERAL investigators want the ability to access patient information in the proposed national real-time prescription monitoring system (PD 16 Apr) in order to help identify "criminal entrepeneurs" who are diverting prescription opioids with the assistance of "complicit" pharmacists and doctors.
-
FDA web warning
Thursday | Jun 7 2018THE US Food and Drug Administration has formally warned nine online networks operating a total of 53 websites that they must "stop illegally marketing potentially dangerous, unapproved and misbranded versions of opioid medications".
-
Dispensary Corner
Thursday | Jun 7 2018
07 Jun 18THE ultimate in unhealthy food combinations has been created in New York (where else!) where a brewing company has joined forces with an ice cream manufacturer.
-
-
S4s dominate RUM
Wednesday | Jun 6 2018MORE than half of returned medicines (55%) in the Return of Unwanted Medicines (RUM) Project bins.
-
Advancing Practice
Wednesday | Jun 6 2018
round 2APPLICATIONS are now being invited for the second round of pharmacists wanting to be recognised under the new centralised Advancing Practice initiative (PD 05 Mar).
-
Blackmores opens Bungarribee
Wednesday | Jun 6 2018BLACKMORES yesterday formally opened its new distribution centre in the western Sydney suburb of Bungarribee.
-
Bod signs with Symbion
Wednesday | Jun 6 2018LISTED natural medicines and medicinal cannabis company Bod Australia has signed a distribution agreement with its second large pharmacy wholesaler, Symbion.
-
Migraine opportunity
Wednesday | Jun 6 2018SUBMISSIONS to the Pharmaceutical Benefits Advisory Committee in relation to a new migraine prevention treatment called Aimovig (erenumab) are due by close of business today.
